QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KRYS

QT69Krystal Biotech, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
348.06
+6.40+1.87%
OverviewShort InterestFilings
KRYSQT69Krystal Biotech, Inc.·NASDAQ
OverviewShort InterestFilings
348.06+1.87%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E44.47EPS (ttm)
7.48
Insider Own12.29%
Shs Outstand29.48M
Perf Week8.24%
Market Cap10.07BForward P/E35.84EPS next Y9.71Insider Trans0.51%Shs Float-Perf Month18.67%
Enterprise Value9.58BPEG0.56EPS next Q1.81Inst Own-Short Float-Perf Quarter34.91%
Income226.62MP/S24.14EPS this Y3.63%Inst Trans-Short Ratio-Perf Half Y45.91%
Sales417.30MP/B7.84EPS next Y25.28%ROA16.11%Short Interest-Perf YTD41.18%
Book/sh43.32P/C39.98EPS next 5Y45.60%ROE19.25%52W High356.51 -2.37%Perf Year167.70%
Cash/sh27.92P/FCF42.43EPS past 3/5Y-ROIC13.85%52W Low127.99 171.94%Perf 3Y-
Dividend Est.-EV/EBITDA47.74Sales past 3/5Y-Gross Margin92.79%Volatility3.03% 2.56%Perf 5Y-
Dividend TTM-EV/Sales22.96EPS Y/Y TTM149.33%Oper. Margin42.85%ATR (14)12.50Perf 10Y-
Dividend Ex-Date-Quick Ratio9.06Sales Y/Y TTM43.30%Profit Margin53.92%RSI (14)73.47Recom2.00
Dividend Gr. 3/5Y-Current Ratio9.46EPS Q/Q52.50%SMA2011.64%Beta0.86Target Price336.40
Payout0.00%Debt/Eq0.01Sales Q/Q31.82%SMA5018.38%Rel Volume2.74Prev Close341.66
Employees275LT Debt/Eq0.01EarningsAug 03SMA20042.54%Avg Volume296.32KPrice348.06
IPO DateSep 20, 2017Option/ShortYes / YesEPS/Sales Surpr.26.21% 3.57%Net Debt/EBITDA-2.45Volume811,262Change1.87%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-16-26ReiteratedH.C. WainwrightBuy$310 → $361
May-05-26ReiteratedEvercore ISI$295 → $300
Feb-18-26ReiteratedChardan CapitalBuy$216 → $323
Feb-17-26ReiteratedJefferiesBuy$371
Jan-09-26ReiteratedH.C. WainwrightBuy$240 → $310
Jan-06-26UpgradeCitigroupNeutral → Buy
Oct-17-25ReiteratedGuggenheimBuy$189 → $224
Aug-22-25ReiteratedChardan CapitalBuy$133 → $216
Sep-11-24ReiteratedStifel Nicolaus$204 → $220
Sep-02-24ReiteratedBank of America Securities$195 → $205
Latest News
Jun-18-26
Jun-18-2610:33AM
TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403Benzinga
Jun-16-26
Jun-16-2611:44AM
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue417389291
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A302920
Gross Profit387360270
Selling, General and Administrative Excl. Other155147114
Research and Development585854
Other Operating Expense-4-637
Operating Income17816166
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-15-28-37
Net Income Before Taxes20718995
Income Taxes-17-156
Consolidated Net Income22420589
Net Income From Continuing Operations22420589
Net Income22420589
EPS (Recurring)7.757.083.12
EPS (Basic, Before Extraordinaries)7.757.083.12
EPS (Diluted)7.486.843.00
EBITDA201196110
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio46.5336.04—
Price To Sales Ratio24.2118.38—
Gross Margin92.8192.5492.78
Operating Margin42.6941.3922.68
Net Margin53.7252.7030.58
Shares Outstanding292929
Market Capitalization10,0947,150—
Operating Lease Expense
———
Insider Trading Volume
$364.11$336.83$309.55$282.28$255.00● Close Price0.00M6.94M13.88M20.82M27.76MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Krishnan Krish SPresident and CEOJun 04 '26Sale308.1225,0007,702,9831,450,253Jun 05 12:00 AM
Krishnan SumaPresident, R&DJun 04 '26Sale308.1125,0007,702,8261,378,155Jun 05 12:00 AM
Thomas John CharlesEVP, General CounselMay 26 '26Sale302.03642193,9030May 27 12:00 AM
Krishnan SumaPresident, R&DMar 04 '26Sale263.2125,0006,580,2691,403,155Mar 06 12:00 AM
Krishnan Krish SPresident and CEOMar 04 '26Sale263.1725,0006,579,1641,475,253Mar 06 12:00 AM
ROMANO KATHRYNChief Accounting OfficerMar 02 '26Sale267.60750200,70022,366Mar 03 12:00 AM
ROMANO KATHRYNChief Accounting OfficerFeb 27 '26Option Exercise0.0016,100026,068Mar 03 12:00 AM
Krishnan SumaPresident, R&DFeb 27 '26Option Exercise0.0093,72501,509,075Mar 03 12:00 AM
Krishnan Krish SPresident and CEOFeb 27 '26Option Exercise0.00107,95001,509,075Mar 03 12:00 AM
JANNEY DANIELDirectorFeb 27 '26Sale275.5911,8033,252,82473,293Mar 03 12:00 AM
JANNEY DANIELDirectorFeb 26 '26Sale275.637,7412,133,67985,096Feb 26 12:00 AM
JANNEY DANIELDirectorFeb 25 '26Sale275.00700192,50092,837Feb 26 12:00 AM
JANNEY DANIELDirectorFeb 24 '26Sale267.2751,72013,823,2020Feb 26 12:00 AM
JANNEY DANIELDirectorFeb 24 '26Option Exercise2.4675,790186,44437,895Feb 26 12:00 AM
ROSSI DINO ADirectorFeb 19 '26Option Exercise8.7937,900333,14097,641Feb 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR